drugset / Trial / NCT06791525

Tirbanibulin for Pediatric Warts

NCT06791525

Phase 4 Recruiting 10 enrolled The Skin Center Dermatology Group
NaSingle-groupOpen-labelTreatment

Summary

Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.

Timeline

Start
2025-05-01
Primary completion
2026-11-01
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirbanibulin Small molecule 1 % Topical

Indications